Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Other

If ‘other’, further details on the scope of the study

To describe diagnosis, barriers to treatment and pharmacological patterns and non-pharmacological treatment patterns of people with migraine in Spain and Germany who meet the International Classification of Headache Disorders (ICHD)-3 criteria.
Non-interventional study

Non-interventional study design

Cross-sectional
Other

Non-interventional study design, other

This study is a non-interventional, cross-sectional observational study with data collected via a web-based survey
Study drug and medical condition

Medical condition to be studied

Migraine
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

22000
Study design details

Main study objective

Research question and objectives: Describe diagnosis, barriers to treatment and pharmacological patterns, as well as non-pharmacological treatment patterns of people with migraine in Spain and Germany who meet the International Classification of Headache Disorders (ICHD)-3 criteria. Secondary objectives aim to evaluate people with migraine regarding certain co-morbidities and migraine risk factors

Outcomes

The primary objective of this research is to understand barriers to treatment, and treatment patterns of people with migraine who met ICHD-3 criteria with subgroups of different frequency of monthly headache days 0-3, 4-7, 8-14, ≥15. 1. Evaluate people with migraine with regard, but not limited to:a. To report the prevalence of cardiovascular related diseases and risk factors associated with migraineb. To understand the driving attitudes and behavior of people with migraine during their attack.c. To understand the proportion of triptan failures and reasons for stoppingd. To compare triptan responder versus insufficient

Data analysis plan

Analyses are grouped into two general categories: cross-sectional cohort analyses and non-migraine population analysis. For key analyses, separate data specification plans will be developed that will provide the analytical methods in detail. For analyses, all data will be used. Descriptive statistics will be conducted to provide summaries for all variables in each cohort and specific subgroups of interest (e.g. monthly headache days). Continuous variables will be summarized as means with standard deviations, or medians and ranges, as appropriate.Categorical variables will be summarized as frequencies and percentages.